Logo image of AFME.PA

AFFLUENT MEDICAL SA (AFME.PA) Stock Fundamental Analysis

EPA:AFME - Euronext Paris - Matif - FR0013333077 - Common Stock - Currency: EUR

1.365  0 (0%)

Fundamental Rating

1

Overall AFME gets a fundamental rating of 1 out of 10. We evaluated AFME against 59 industry peers in the Health Care Equipment & Supplies industry. AFME has a bad profitability rating. Also its financial health evaluation is rather negative. AFME is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AFME has reported negative net income.
AFME had a negative operating cash flow in the past year.
AFME had negative earnings in each of the past 5 years.
In the past 5 years AFME always reported negative operating cash flow.
AFME.PA Yearly Net Income VS EBIT VS OCF VS FCFAFME.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -24.22%, AFME is not doing good in the industry: 74.58% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -48.69%, AFME is doing worse than 72.88% of the companies in the same industry.
Industry RankSector Rank
ROA -24.22%
ROE -48.69%
ROIC N/A
ROA(3y)-25.74%
ROA(5y)-24.09%
ROE(3y)-47.78%
ROE(5y)-43.59%
ROIC(3y)N/A
ROIC(5y)N/A
AFME.PA Yearly ROA, ROE, ROICAFME.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

AFME's Gross Margin of 20.79% is on the low side compared to the rest of the industry. AFME is outperformed by 86.44% of its industry peers.
The Profit Margin and Operating Margin are not available for AFME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AFME.PA Yearly Profit, Operating, Gross MarginsAFME.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

2

2. Health

2.1 Basic Checks

AFME does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AFME has been increased compared to 1 year ago.
The number of shares outstanding for AFME has been increased compared to 5 years ago.
AFME has a better debt/assets ratio than last year.
AFME.PA Yearly Shares OutstandingAFME.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2019 2020 2021 2022 2023 2024 10M 20M 30M
AFME.PA Yearly Total Debt VS Total AssetsAFME.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

AFME has an Altman-Z score of -0.89. This is a bad value and indicates that AFME is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.89, AFME is not doing good in the industry: 79.66% of the companies in the same industry are doing better.
AFME has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AFME (0.48) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z -0.89
ROIC/WACCN/A
WACC7%
AFME.PA Yearly LT Debt VS Equity VS FCFAFME.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.28 indicates that AFME should not have too much problems paying its short term obligations.
With a Current ratio value of 1.28, AFME is not doing good in the industry: 67.80% of the companies in the same industry are doing better.
AFME has a Quick Ratio of 1.28. This is a normal value and indicates that AFME is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.28, AFME perfoms like the industry average, outperforming 59.32% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 1.28
AFME.PA Yearly Current Assets VS Current LiabilitesAFME.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

AFME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.69%, which is quite impressive.
EPS 1Y (TTM)23.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AFME will show a very negative growth in Earnings Per Share. The EPS will decrease by -23.52% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-69.76%
EPS Next 2Y-23.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AFME.PA Yearly Revenue VS EstimatesAFME.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2024 2026 1M 2M 3M 4M
AFME.PA Yearly EPS VS EstimatesAFME.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AFME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AFME. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AFME.PA Price Earnings VS Forward Price EarningsAFME.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFME.PA Per share dataAFME.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as AFME's earnings are expected to decrease with -23.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.52%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AFME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AFFLUENT MEDICAL SA

EPA:AFME (6/20/2025, 7:00:00 PM)

1.365

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners10.03%
Ins Owner ChangeN/A
Market Cap53.71M
Analysts86
Price Target3.88 (184.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.59%
PT rev (3m)-5.59%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-53.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.04
P/FCF N/A
P/OCF N/A
P/B 1.77
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.1
BVpS0.77
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.22%
ROE -48.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.79%
FCFM N/A
ROA(3y)-25.74%
ROA(5y)-24.09%
ROE(3y)-47.78%
ROE(5y)-43.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.1%
Cap/Sales 3.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 1.28
Altman-Z -0.89
F-Score6
WACC7%
ROIC/WACCN/A
Cap/Depr(3y)6.62%
Cap/Depr(5y)10.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.5%
EPS Next Y-69.76%
EPS Next 2Y-23.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.06%
OCF growth 3YN/A
OCF growth 5YN/A